Identifying the underlying mechanisms and consequences of the loss of nasal Immune cells in vital and frail older individuals

Identifying the underlying mechanisms and consequences of the loss of nasal T cells in vital and frail older individuals - T cells in Nose of Older adults (TINO)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON54081

Enrollment

170

Registered

2021-06-02

Start date

2022-01-24

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

respiratory infections in elderly

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Age, frailty score and self-reported respiratory tract infections in previous year, ability to provide informed consent

Exclusion criteria

Exclusion criteria: • Incompetence to provide informed consent • Current smoker or >40 pack year history • History of severe nose bleedings • Diagnosed with asthma, COPD or chronic rhinosinusitis • Use of inhalation corticosteroids or antibiotics in the past 6 weeks • Current use of anti-coagulants (to prevent nosebleeds). Platelet inhibitors like acetylsalicylzuur (Ascal) are allowed • Respiratory tract infection or common cold in the past 2 weeks • Immunocompromised individuals (with primary immune deficiency or secondary immune deficiency) • Life expectancy

Design outcomes

Primary

Measure	Time frame
Frequency of nasal CD8+ T cells in young adults and frail older adults.	—

Secondary

Measure	Time frame
• Phenotype (subsets, activation status), functionality, transcriptomic state, clonality and frequency of nasal and blood T cell populations in young adults, healthy older adults and frail older adults that suffer from recurrent respiratory tract infections or not. • Stability of T cells and other immune parameters, as described for main study parameter, during a second sample after 3 months. • Analysis of other immune populations as for main study parameter • Concentration of nasal and systemic factors (e.g. cytokines and metabolites) and their association with T cells and other immune populations • Respiratory tract microbiota profiles and presence of asymptomatic viral infections and their association with T cells and other immune parameters • Chronological and biological age, sex, and other immunologically relevant parameters with T cell populations and other immune parameters • Alteration of T cell phenotype, during and following respiratory tract infections. Levels of antigen-specific T cells and other immune parameters in nose and blood post infection. Aetiological agent will be characterized using standard diagnostics tests.	—

Measure

Time frame

• Phenotype (subsets, activation status), functionality, transcriptomic state, clonality and frequency of nasal and blood T cell populations in young adults, healthy older adults and frail older adults that suffer from recurrent respiratory tract infections or not. • Stability of T cells and other immune parameters, as described for main study parameter, during a second sample after 3 months. • Analysis of other immune populations as for main study parameter • Concentration of nasal and systemic factors (e.g. cytokines and metabolites) and their association with T cells and other immune populations • Respiratory tract microbiota profiles and presence of asymptomatic viral infections and their association with T cells and other immune parameters • Chronological and biological age, sex, and other immunologically relevant parameters with T cell populations and other immune parameters • Alteration of T cell phenotype, during and following respiratory tract infections. Levels of antigen-specific T cells and other immune parameters in nose and blood post infection. Aetiological agent will be characterized using standard diagnostics tests.

—

Countries

Netherlands

Contacts

Public ContactS.P Jochems

Universiteit Leiden

s.p.jochems@lumc.nl+31 (0) 71 526 1328

Outcome results